Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China
- PMID: 24006443
- PMCID: PMC3807931
- DOI: 10.1128/JVI.02127-13
Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China
Abstract
A nationwide hepatitis B virus (HBV) vaccination program was implemented in China starting in 1992. To study the change in HBV variant prevalence with massive immunization, large HBV surface protein (LHBs) genes from HBV surface antigen (HBsAg)-positive sera were amplified and sequenced. The prevalences of LHBs mutants were compared between the 1992 and 2005 surveys in child and adult groups. The prevalence of "α" determinant mutants in the children increased from 6.5% in 1992 to 14.8% in 2005, where the G145R mutant occurred most frequently. In contrast, mutation frequencies showed little difference between 1992 (9.4%) and 2005 (9.9%) in adults. Moreover, compared to the 1992 survey, the child group surface (S) protein mutation frequency specifically increased (P = 0.005) in the 2005 survey, but the pre-S region mutation frequency did not show a significant difference (P > 0.05). However, the mutation frequency in the adult group increased in both the pre-S and S regions. Furthermore, the frequencies of the disease-related pre-S2 deletion and start codon mutations were significantly higher in the adult groups than in the child groups in both the 1992 and 2005 surveys (P < 0.01). Massive immunization enhances the HBV S protein mutation; the prevalence of LHBs mutants, particularly disease-related mutants, tends to increase with patient age.
Figures
Comment in
-
Reduced prevalence of HBsAg variants following a successful immunization program in China.J Virol. 2014 Apr;88(8):4605-6. doi: 10.1128/JVI.03654-13. J Virol. 2014. PMID: 24672049 Free PMC article. No abstract available.
-
Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance.J Virol. 2014 Jun;88(11):6532. doi: 10.1128/JVI.00234-14. J Virol. 2014. PMID: 24803487 Free PMC article. No abstract available.
References
-
- Ganem D, Prince AM. 2004. Hepatitis B virus infection—natural history and clinical consequences. N. Engl. J. Med. 350:1118–1129 - PubMed
-
- Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45:529–538 - PubMed
-
- Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. 2009. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J. Infect. Dis. 200:39–47 - PubMed
-
- Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. 2009. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 27:6550–6557 - PubMed
-
- Li RC, Yang JY, Gong J, Li YP, Huang ZN, Fang KX, Xu ZY, Liu CB, Zhao K, Zhuang H. 2004. Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi 25:385–387 (In Chinese.) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
